SCHEMBL5136471

SCHEMBL5136471

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(CO)cc1CO

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
TSHR P16473 2/20 0.38
PGR P06401 1/20 0.37
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HDAC1 Q13547 2/20 0.33
HSD11B1 P28845 2/20 0.33
PDE4B Q07343 2/20 0.33
AGTR1 P30556 1/20 0.33
PPARG P37231 1/20 0.33
CRHR1 P34998 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136482 0.90 C5AR1 (0.47) C5AR1TSHRPGRKDM4EALDH1A1
SCHEMBL5135130 0.89 C5AR1 (0.48) C5AR1TSHRPGRKDM4EALDH1A1
SCHEMBL5135330 0.86 C5AR1 (0.43) C5AR1TSHRPGRKDM4EALDH1A1
SCHEMBL651094 0.86 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135922 0.85 C5AR1 (0.49) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5138072 0.85 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135312 0.84 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135444 0.84 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5134746 0.84 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5073888 0.84 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed